Proteome Sciences plc
PRM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.02 | 0.00 | -3.22 |
| FCF Yield | -10.46% | -5.38% | 19,800.89% | 47,468.78% |
| EV / EBITDA | -15.47 | -21.80 | 8.80 | 44.55 |
| Quality | ||||
| ROIC | -29.28% | -15.13% | 14.18% | 2.67% |
| Gross Margin | 13.71% | 32.76% | 0.02% | 0.01% |
| Cash Conversion Ratio | 0.24 | 0.20 | 2,929.81 | 146,138.89 |
| Growth | ||||
| Revenue 3-Year CAGR | -94.10% | -93.94% | 11.89% | 4.62% |
| Free Cash Flow Growth | -46.24% | -100.03% | -75.73% | 197.07% |
| Safety | ||||
| Net Debt / EBITDA | -8.84 | -10.07 | 3.73 | 14.88 |
| Interest Coverage | -2.63 | -2.03 | 3.65 | 1.40 |
| Efficiency | ||||
| Inventory Turnover | 5.76 | 4.04 | 3.34 | 1.99 |
| Cash Conversion Cycle | 46.07 | 118.11 | 27.77 | 120.00 |